As a treatment goal for your adult patients with anti-AQP4 antibody-positive NMOSD,

Zero relapses were seen in the CHAMPION-NMOSD study¹*

ULTOMIRIS^® significantly reduced the risk of relapse by 98.6% vs the placebo arm (HR 0.014; 95% CI: 0.000-0.103), based on time to first adjudicated on-trial relapse (primary endpoint; P<0.0001)¹

*Observed during the primary treatment period, which ended when the last patient completed 50 weeks and included a median study duration of 73.5 weeks (min 13.7, max 117.7).¹

Efficacy

In anti-AQP4 antibody-positive NMOSD, ULTOMIRIS is the first and only fast-acting and long-acting C5 inhibitor^1,2

Provides immediate, complete, and sustained inhibition of C5^1,2†

Long-acting C5 inhibition observed as early as <1 hour after the first infusion

Mechanism of Action

^†Complete inhibition of serum-free C5 (concentration of <0.5 μg/mL) was observed by the end of the first ULTOMIRIS infusion and sustained throughout the entire 26-week treatment period in the majority (98.3%) of adult patients with anti-AQP4 antibody-positive NMOSD.¹

Once-every-8-week maintenance dosing starting 2 weeks after loading dose¹

Each maintenance infusion typically lasts <1 hour for the majority of patients^‡

Dosing

^‡The minimum infusion time for ULTOMIRIS maintenance doses ranges from 30 minutes to 1 hour, depending on body weight. Patients are monitored for at least 1 hour after infusions, for signs or symptoms of an infusion-related reaction. If an adverse reaction occurs during the intravenous administration of ULTOMIRIS, the infusion may be slowed or stopped at the discretion of the physician.¹

AQP4, aquaporin-4; CI, confidence interval; HR, hazard ratio; NMOSD, neuromyelitis optica spectrum disorder.

Zero in on the CHAMPION-NMOSD trial data

Discover the breakdown of patient subgroups from the CHAMPION-NMOSD trial and the number of relapses they experienced before and during the study.

Subgroup Data

ULTOMIRIS is an established complement inhibitor with evidence and experience across multiple indications¹

> 700
PATIENTS
STUDIED IN CLINICAL TRIALS^1,3

7 Clinical
trials

across 4 rare, complement-mediated diseases^1,3

7 + years

of postmarketing experience¹

34,000+
patient-years of experience in the real world⁴

Strive for Zero with ULTOMIRIS

Start Your Patients

As a treatment goal for your adult patients with anti-AQP4 antibody-positive NMOSD,

Zero relapses were seen in the CHAMPION-NMOSD study¹*

In anti-AQP4 antibody-positive NMOSD, ULTOMIRIS is the first and only fast-acting and long-acting C5 inhibitor^1,2

Provides immediate, complete, and sustained inhibition of C5^1,2†

Long-acting C5 inhibition observed as early as <1 hour after the first infusion

Once-every-8-week maintenance dosing starting 2 weeks after loading dose¹

Each maintenance infusion typically lasts <1 hour for the majority of patients^‡

Zero in on the CHAMPION-NMOSD trial data

ULTOMIRIS is an established complement inhibitor with evidence and experience across multiple indications¹

Strive for Zero with ULTOMIRIS

IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

Alexion Connect

As a treatment goal for your adult patients with anti-AQP4 antibody-positive NMOSD,

Zero relapses were seen in the CHAMPION-NMOSD study1*

In anti-AQP4 antibody-positive NMOSD, ULTOMIRIS is the first and only fast-acting and long-acting C5 inhibitor1,2

Provides immediate, complete, and sustained inhibition of C51,2†

Long-acting C5 inhibition observed as early as <1 hour after the first infusion

Once-every-8-week maintenance dosing starting 2 weeks after loading dose1

Each maintenance infusion typically lasts <1 hour for the majority of patients‡

Zero in on the CHAMPION-NMOSD trial data

ULTOMIRIS is an established complement inhibitor with evidence and experience across multiple indications1

Strive for Zero with ULTOMIRIS

IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

Alexion Connect

Zero relapses were seen in the CHAMPION-NMOSD study¹*

In anti-AQP4 antibody-positive NMOSD, ULTOMIRIS is the first and only fast-acting and long-acting C5 inhibitor^1,2

Provides immediate, complete, and sustained inhibition of C5^1,2†

Once-every-8-week maintenance dosing starting 2 weeks after loading dose¹

Each maintenance infusion typically lasts <1 hour for the majority of patients^‡

ULTOMIRIS is an established complement inhibitor with evidence and experience across multiple indications¹